February 12, 2020 / 6:31 AM / 9 days ago

BRIEF-Carmat Says Cash Position Is 55.5 Million Euros At December 31, 2019

Feb 12 (Reuters) - Carmat SA:

* REPORTS ITS 2019 ANNUAL RESULTS AND CONFIRMS ITS 2020 OBJECTIVES

* FULL FDA APPROVAL FOR A CLINICAL FEASIBILITY STUDY IN UNITED STATES, WITH ENROLLMENT EXPECTED TO BEGIN IN Q4 OF 2020

* OPERATING EXPENSES UNDER CONTROL IN A CONTEXT OF INTENSIFYING EUROPEAN MARKET ACCESS STRATEGY

* STRONG CASH POSITION OF EUR 55.5 MILLION AT DECEMBER 31, 2019, PROVIDING FINANCIAL VISIBILITY UNTIL MID-2021

* FUNDS HAVE PROVIDED US WITH A FINANCIAL VISIBILITY THROUGH TO MID-2021 NOTABLY INCLUDING OUR KEY OBJECTIVE OF OBTAINING CE MARKING IN 2020 - CEO Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below